当前位置: 首页 >> 检索结果
201. Pancarditis and fibrosis as hallmarks of lupus myocarditis: clinical features, imaging findings and outcomes.
作者: María Del Carmen Zamora-Medina.;Erik Cimé-Aké.;Emilio Godínez-Lazarini.;Wallace Rafael A Muñoz-Castañeda.;Griselda Medina-Montaño.;Hilda Fragoso-Loyo.
来源: Rheumatology (Oxford). 2026年65卷2期
To describe and compare the clinical features, imaging findings and outcomes of lupus myocarditis (LM) patients with those of active systemic lupus erythematosus (SLE) without myocarditis (SLE-non-LM) and acute myocarditis non-autoimmune (AM-non-AI) patients.
202. The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established cs DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study.
作者: Joanne Ablewhite.;Georgina Nakafero.;Abdullah Almayahi.;Katie Bechman.;Alison Ahmed.;Alan Davidson.;Hope De Vere.;Emmandeep Dhillon.;Amy Foulkes.;Nicola Gullick.;Rebecca Heaton.;Samantha Hider.;Stuart Kyle.;Kataryzna Nowak.;Emily Rose-Parfitt.;Sarah Ryan.;Su Yin Tan.;Natasha Wood.;Genevieve Zebate.;Kate Parsons.;Julia Holmes.;Helen Twohigg.;John A Reynolds.;Louise Mercer.;James Galloway.;Abhishek Abhishek.
来源: Rheumatology (Oxford). 2026年65卷2期
To explore how appropriate different intervals between monitoring blood tests are considered in relation to the risk of clinically significant adverse drug reactions in adults prescribed conventional synthetic DMARDs (csDMARDs) for ≥1 year for systemic autoimmune rheumatic diseases (SARD).
203. Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study.
作者: Yu Xue.;Lingyun Sun.;Ning Zhang.;Haiying Chen.;Xiaofei Shi.;Shengyun Liu.;Lin Chen.;Xinmei Ma.;Hua Wei.;Zhenyu Jiang.;Xiaomei Li.;Hongtao Fan.;Hongbin Li.;Jingyang Li.;Rui Wu.;Guixiu Shi.;Jing Zhu.;Xiaodan Kong.;Yuewu Lu.;Pan Liu.;Qianning Zheng.;Xiaoyan Bai.;Su Zhang.;Weiguo Wan.;Hejian Zou.
来源: Rheumatology (Oxford). 2026年65卷2期
Current PsA therapies, from conventional agents (e.g. MTX) to targeted biologics (e.g. TNF and IL-17 inhibitors), demonstrate distinct therapeutic profiles. Vunakizumab (SHR-1314) is a novel humanized mAb targeting IL-17A. The phase 2 trial evaluated the efficacy and safety of vunakizumab in patients with active PsA.
204. Redundant radiography before CT in axial spondyloarthritis: high radiation burden, limited diagnostic value.
作者: Elif Kurtulus.;Tuba Yuce Inel.;Ozkan Urak.;Ali Balci.;Ismail Sari.
来源: Rheumatology (Oxford). 2026年65卷2期
The objectives of this study were to quantify the number and cumulative radiation dose of pelvic and lumbar radiographs obtained before sacroiliac CT confirmed diagnosis of radiographic axial SpA (r-axSpA), and to assess potential dose reduction if CT had been used instead of repeated radiographs.
205. Interspinous ligamentitis in patients with psoriatic arthritis.
Axial involvement in psoriatic arthritis (axPsA) is common but is more heterogeneous than classical axial spondyloarthritis (axSpA). Posterior soft-tissue inflammation is a potential cause of back pain in axPsA. Here, we report a case series illustrating this presentation.
206. White matter abnormalities in an MRI-based study in Behçet's syndrome: incidental findings or clinically relevant?
作者: Rosaria Talarico.;Federica Di Cianni.;Tommaso Calzoni.;Valentina Lorenzoni.;Mirco Cosottini.;Marta Mosca.
来源: Rheumatology (Oxford). 2026年65卷2期
This study aimed to assess prevalence, distribution, severity and clinical correlates of white matter abnormalities (WMAs) at brain magnetic resonance imaging (bMRI) in Behçet's syndrome patients without active Neuro-Behçet's syndrome (NBS).
208. Early screening for rheumatoid arthritis-associated interstitial lung disease: statistical nuances challenge the role of disease activity - Authors' reply.
作者: Gregory C McDermott.;Misti L Paudel.;Marcy B Bolster.;Kevin D Deane.;Dinesh Khanna.;Bryant R England.;Jeffrey A Sparks.
来源: Lancet Rheumatol. 2026年8卷3期e165-e166页 212. Risk stratifying systemic sclerosis-related pulmonary hypertension by left atrial strain.
作者: Justin K Lui.;Matthew Cozzolino.;Morgan Winburn.;Marcin A Trojanowski.;Michael P LaValley.;Andreea M Bujor.;Deepa M Gopal.;Elizabeth S Klings.
来源: Rheumatology (Oxford). 2026年65卷2期
The objective of the study was to explore left atrial (LA) strain, a quantitative index of left ventricular (LV) diastolic function, in risk stratifying patients with SSc-related pulmonary hypertension (SSc-PH).
214. Comment on: Key factors contributing to gender inequity in global rheumatology awards: a global survey analysis: reply.
作者: Lekshmi Minikumari Rahulan.;Laura C Coates.;Laura Andreoli.;Jessica Day.;Shikha Singla.;Praggya Yaadav.;Arsh E Bareen Khan.;Debaditya Roy.;Vikas Agarwal.;Grace Wright.;Pavel Ovseiko.;Latika Gupta.
来源: Rheumatology (Oxford). 2026年65卷2期 217. Long-term safety and efficacy of tocilizumab in adult-onset Still's disease: open-label, long-term extension of the phase III trial.
作者: Koji Suzuki.;Hideto Kameda.;Kei Ikeda.;Tomonori Ishii.;Kosaku Murakami.;Hyota Takamatsu.;Yoshiya Tanaka.;Takayuki Abe.;Tsutomu Takeuchi.;Yuko Kaneko.
来源: Rheumatology (Oxford). 2026年65卷2期
To investigate the long-term safety and efficacy of tocilizumab, an IL-6 receptor inhibitor, in patients with adult-onset Still's disease.
218. Validation of the revised definition of lupus low disease activity in patients with SLE.
作者: Ji-Hyoun Kang.;Sung-Eun Choi.;Dong-Jin Park.;Shin-Seok Lee.
来源: Rheumatology (Oxford). 2026年65卷2期
EULAR recently updated its recommendation for managing SLE by redefining the lupus low disease activity state (LLDAS) with a reduced allowable glucocorticoid dose of ≤5 mg. No studies have validated this revised definition. Thus, we aimed to evaluate its association with clinical outcomes, including organ damage, disease flares and quality of life.
|